ALX Oncology has announced new data from a Phase Ib/II clinical trial of its CD47-inhibitor, evorpacept, combined with Jazz Pharmaceuticals’ Ziihera in heavily pretreated patients with HER2-mBC. The post ALX Oncology announces Phase Ib/II trial results for breast cancer appeared first on Hospital Management.
ALX Oncology has announced new data from a Phase Ib/II clinical trial of its CD47-inhibitor, evorpacept, combined with Jazz Pharmaceuticals’ Ziihera in heavily pretreated patients with HER2-mBC.The post ALX Oncology announces Phase Ib/II trial results for breast cancer appeared first on Hospital Management.
